Hologic price target raised to $84 from $82 at Morgan Stanley

Morgan Stanley analyst Tejas Savant raised the firm’s price target on Hologic to $84 from $82 and keeps an Equal Weight rating on the shares. The firm cites the modest beat in Q1 despite fewer selling days impact and the modestly raised FY24 outlook, with all segments expected to grow in the +5%-7% range.